Literature DB >> 18536554

Antibody engineering principles and applications.

LiNa Loo1, Matthew K Robinson, Gregory P Adams.   

Abstract

Antibodies have emerged as significant agents for the treatment of a number of diseases including cancer and autoimmunity. However, most of the antibodies currently used in clinical practice were developed from humanized or chimeric molecules based on mouse monoclonal antibodies. Recent advances in antibody selection and engineering techniques have led to the development of antibodies specific for highly conserved targets, the creation of novel antibody-based structures, significant improvements in affinity for target antigens, enhanced ability to engage immune effector functions, and the creation of fusion proteins with direct cytotoxic properties. This review provides an overview of the techniques that we expect will have the greatest impact on the field of antibody engineering.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18536554     DOI: 10.1097/PPO.0b013e318173a5d5

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  6 in total

1.  Recombinant antibodies specific for the Plasmodium falciparum histidine-rich protein 2.

Authors:  Elisabeth Ravaoarisoa; Halima Zamanka; Thierry Fusai; Jacques Bellalou; Hugues Bedouelle; Odile Mercereau-Puijalon; Thierry Fandeur
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

Review 2.  Bridging the gap: facilities and technologies for development of early stage therapeutic mAb candidates.

Authors:  Trent P Munro; Stephen M Mahler; Edwin P Huang; David Y Chin; Peter P Gray
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

Review 3.  Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.

Authors:  Henrik Gensicke; David Leppert; Özgür Yaldizli; Raija L P Lindberg; Matthias Mehling; Ludwig Kappos; Jens Kuhle
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

4.  A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression.

Authors:  Gang Ren; Rong Zhang; Zhe Liu; Jack M Webster; Zheng Miao; Sanjiv S Gambhir; Faisal A Syud; Zhen Cheng
Journal:  J Nucl Med       Date:  2009-08-18       Impact factor: 10.057

Review 5.  Affinity and avidity in antibody-based tumor targeting.

Authors:  Stephen I Rudnick; Gregory P Adams
Journal:  Cancer Biother Radiopharm       Date:  2009-04       Impact factor: 3.099

6.  MAPs: a database of modular antibody parts for predicting tertiary structures and designing affinity matured antibodies.

Authors:  Robert J Pantazes; Costas D Maranas
Journal:  BMC Bioinformatics       Date:  2013-05-30       Impact factor: 3.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.